Should I invest in Franklin Pharma Fund?

We don't give personal investment advice. Franklin Pharma Fund - Growth is suitable for an investor whose:understands what asset class this scheme actually invests in (check the factsheet)matches that asset class's volatility profile to their goal horizonCross-check the numbers above against alternatives before deciding. 5-year CAGR: -100.00%.

Franklin Templeton

Franklin Pharma Fund - Growth

Returns matrix

Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).

Window	Fund	Category avg	+/− vs avg	Rank	Quartile
1D	—	—	—	—	—
1W	-100.00%	-3.61%	-96.39	299 / 303	Q4
2W	-100.00%	-4.52%	-95.48	299 / 303	Q4
1M	-100.00%	-5.64%	-94.36	298 / 302	Q4
3M	-100.00%	-4.27%	-95.73	298 / 302	Q4
6M	-100.00%	+1.48%	-101.48	303 / 307	Q4
YTD	-100.00%	-0.18%	-99.82	305 / 309	Q4
1Y	-100.00%	+7.10%	-107.10	303 / 307	Q4
2Y	-100.00%	+2.20%	-102.20	297 / 303	Q4
3Y	-100.00%	+0.76%	-100.76	258 / 264	Q4
4Y	-100.00%	+0.58%	-100.58	229 / 235	Q4
5Y	-100.00%	+0.02%	-100.02	202 / 208	Q4
7Y	—	—	—	—	—
10Y	—	—	—	—	—
Inception	-100.00%	+0.51%	-100.51	303 / 310	Q4

Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%

Calendar-year returns

Full-year performance vs category average. Current year is partial (year-to-date).

Year	Fund	Category avg	+/− vs avg	Rank
2011 YTD	-100.00%	-23.68%	-76.32	241 / 241
2010	+37.03%	+11.69%	+25.35	2 / 256
2009	+111.20%	+65.86%	+45.34	10 / 238
2008	-27.40%	-52.86%	+25.46	17 / 198
2007	+5.57%	+42.91%	-37.35	127 / 137
2006	—	—	—	—

Rolling returns

Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.

1-Year rolling

+27.39%

54 windows

min -27.2% · max 155.8%

65% positive

Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.

3-Year rolling

+22.10%

29 windows

min -5.8% · max 33.8%

97% positive

Limited basis — fund is young, so this average may be skewed by which 3Y windows happen to be available.

5-Year rolling

+19.80%

5 windows

min 16.3% · max 23.6%

100% positive

Limited basis — fund is young, so this average may be skewed by which 5Y windows happen to be available.

7-Year rolling

—

Insufficient history

Recent NAVs

Date	NAV
12 Sep 2011	₹0.0000
9 Sep 2011	₹61.6191
8 Sep 2011	₹61.8653
7 Sep 2011	₹61.8090
6 Sep 2011	₹61.6758
5 Sep 2011	₹61.7921
2 Sep 2011	₹62.0065
30 Aug 2011	₹61.7840
29 Aug 2011	₹61.4529
26 Aug 2011	₹60.9535

Frequently asked questions

These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.

Franklin Pharma Fund - Growth is a Growth from Franklin Templeton (Unknown plan, Growth option). Latest NAV isn't currently available in our feed — the AMC publishes it once per business day after market close.

Franklin Pharma Fund - Growth has NAV history starting from 03 Apr 2006, a track record of about 20 years 2 months. Long-tenured funds like this have weathered multiple market cycles — the 2008 crash, 2013 taper tantrum, 2020 COVID drawdown — which makes their returns more credible than a 3-year track record alone.

Franklin Pharma Fund - Growth is managed by Franklin Templeton. It's classified by AMFI under the 'Growth' SEBI category, which determines its peer set and tax treatment.

Over the trailing 1-year window, Franklin Pharma Fund - Growth has delivered a absolute return of -100.00% — -107.1 pp behind the Growth category average of 7.10%. The fund ranks #303 of 307 in its category — the bottom (Q4) quartile.

Over the trailing 3-year window, Franklin Pharma Fund - Growth has delivered a CAGR of -100.00% — -100.76 pp behind the Growth category average of 0.76%. The fund ranks #258 of 264 in its category — the bottom (Q4) quartile.

Over the trailing 5-year window, Franklin Pharma Fund - Growth has delivered a CAGR of -100.00% — -100.02 pp behind the Growth category average of 0.02%. The fund ranks #202 of 208 in its category — the bottom (Q4) quartile.

₹1 lakh invested in Franklin Pharma Fund - Growth exactly 5 years ago would be worth approximately ₹0 today — a multiplier of 0.00×, based on the 5-year CAGR of -100.00%. The category average over the same window would have grown ₹1 lakh to ₹100,100.

We don't have enough NAV history yet to simulate a SIP on Franklin Pharma Fund - Growth. The fund typically needs 12+ months for a 1-year SIP backtest.

Franklin Pharma Fund - Growth doesn't have enough SIP-backtest history yet. Check the 1-year SIP simulation above as soon as it has 12+ months of NAVs.

On a 5-year basis, Franklin Pharma Fund - Growth ranks #202 out of 208 funds in the Growth category — that places it in the bottom quartile (Q4) — material underperformance. The category average return over the same window is 0.02%; this fund delivered -100.00%.

Franklin Pharma Fund - Growth doesn't have a computed drawdown figure yet.

Across all 5-year rolling windows, Franklin Pharma Fund - Growth averaged 19.80% (best 23.60%, worst 16.35%). 100% of rolling windows ended positive.

In calendar year 2010, Franklin Pharma Fund - Growth returned 37.03% — beating the Growth category average of 11.69% by 25.35 pp. It ranked #2 of 256 in its category that year.

Franklin Pharma Fund - Growth doesn't fit cleanly into the standard Equity/Debt buckets in our taxonomy. Tax treatment depends on actual asset allocation as disclosed by the AMC — check the factsheet or AMFI's classification table.

We don't give personal investment advice. Franklin Pharma Fund - Growth is suitable for an investor whose:

understands what asset class this scheme actually invests in (check the factsheet)
matches that asset class's volatility profile to their goal horizon

Cross-check the numbers above against alternatives before deciding. 5-year CAGR: -100.00%.

Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.